Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery and development, ...

In March 2026, Citeline announced an expanded strategic partnership with Recursion Pharmaceuticals to integrate Citeline's real-world data and evidence into Recursion’s tech-enabled drug discovery and ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Nvidia is looking to increase the adoption of AI by biotechnology companies, which could boost its shares, per Goldman Sachs.

Had they included just one of Tony Hoare’s achievements, many scientific careers would be considered prestigious enough. His had a long list, unfortunately closed by his passing away at the age of 92 ...

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Event driven snapshot of Recursion Pharmaceuticals Recursion Pharmaceuticals (RXRX) shares have been drawing attention after ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

After founding the "Google for LLMs," You.com, Richard Socher's next company, Recursive AI, could automate AI research itself ...